Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACZONE for Tarceva-Induced Rash in NSCLC
NCT00343187Phase 2Terminated
- Sponsor
- Allergan
- Start
- Jun 2006
- Primary completion
- Jul 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in drug eruption comparing ACZONE Gel 5% with Vehicle Control (2 arms). Primary endpoints: Adverse Events at 10 weeks, Laboratory Parameters at 10 weeks and 2 more. Started Jun 2006; status: terminated.
02
Drugs
dapsone
03
Conditions
drug eruption
Beyond the preview
Go deeper on NCT00343187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00343187.